Newron Pharmaceuticals S.p.A. Announces 2023 Financial Results and Provides Outlook for 2024

Newron Pharmaceuticals S.p.A., focused on creating novel therapies for central and peripheral nervous system diseases, disclosed its financial outcomes and operational highlights for 2023, offering a glimpse into its anticipations for 2024. Key achievements include significant progress in evenamide development for treatment-resistant schizophrenia, with robust efficacy results reported. Additionally, Newron successfully negotiated agreements with generic pharmaceutical manufacturers in the US concerning its Parkinson’s disease treatment, Xadago®/safinamide, and saw the approval of Supplementary Protection Certificates in Europe.

Corporate developments included strengthening the senior management team and appointing new board advisors and directors, alongside entering into a financial agreement to support operations going forward. The company reported a net loss of EUR 16.2 million for 2023, a slight improvement from the previous year, with decreased operating activity costs and an increase in Xadago® revenues.

Looking ahead, Newron plans to initiate a pivotal trial for evenamide in treating schizophrenia, supported by promising study results and financial resources expected to sustain operations into 2025. Furthermore, discussions continue regarding potential collaborations that could expand Newron’s developmental pipeline.